前列腺癌.pdf

1、Saturday,March 1,2025ModeratorNeil Love,MDRahul Aggarwal,MDAditya Bardia,MD,MPHMitesh J Borad,MDVirginia F Borges,MD,MMScHarold J Burstein,MD,PhDRashmi Chugh,MDChristopher Flowers,MD,MSFacultyJonathan Goldman,MDNicole Lamanna,MDNatasha B Leighl,MD,MMSc Amit Mahipal,MD,MPH William K Oh,MD David M OMa

2、lley,MD Joyce OShaughnessy,MD Krish Patel,MDRichard F Riedel,MD Kerry A Rogers,MD Simron Singh,MD,MPHBrian M Slomovitz,MD Jonathan Strosberg,MD Fourth Annual National General Medical Oncology SummitModule 5:EGFR Mutation-Positive Non-Small Cell Lung CancerCurrent Management of Nonmetastatic and Meta

3、static EGFR Mutation-Positive Non-Small Cell Lung Cancer(NSCLC)Dr LeighlPromising Novel Agents in Clinical Development;EGFR Exon 20 Mutation-Positive NSCLC Dr GoldmanModule 5:EGFR Mutation-Positive Non-Small Cell Lung CancerCurrent Management of Nonmetastatic and Metastatic EGFR Mutation-Positive No

4、n-Small Cell Lung Cancer(NSCLC)Dr LeighlPromising Novel Agents in Clinical Development;EGFR Exon 20 Mutation-Positive NSCLC Dr GoldmanCurrent Management of Nonmetastatic and Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer(NSCLC)Natasha Leighl MD MMSc FRCPC FASCOProfessor of Medicine,Uni

5、versity of TorontoLung Medical Oncology Site Lead,OSI Pharmaceuticals Foundation ChairPrincess Margaret Cancer Centre,Toronto,CanadaDisclosuresNo relevant conflicts of interest to disclose.EGFR-directed therapy now appropriate across stagesStage IB-IIIA resected Stage III unresectable Stage IV Front

6、-Line Stage IV 2nd lineADAURAAdjuvant OsimertinibLAURAConsolidation OsimertinibFLAURAOsimertinibFLAURA2Osimertinib+ChemotherapyMARIPOSAAmivantamab+LazertinibMARIPOSA-2Amivantamab+ChemotherapyADAURA:adjuvant osimertinib x 3 years in patients with resected stage IB(3 cm,high risk)-IIIA EGFR-mutated lu